Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 6/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5139522 | 0.91 | TGFBR1 (0.48) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL3242826 | 0.83 | TGFBR1 (0.55) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL5930906 | 0.82 | SNCA (0.46) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL5138649 | 0.81 | TGFBR1 (0.41) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL5138425 | 0.79 | DCUN1D1 (0.40) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL5138587 | 0.79 | TGFBR1 (0.39) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL5138410 | 0.79 | TGFBR1 (0.39) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL5138590 | 0.79 | TGFBR1 (0.39) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL5138816 | 0.78 | KDM4E (0.43) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL4032916 | 0.78 | TGFBR1 (0.40) | TGFBR1MAPK14RIPK2ACVR1BTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1804801-A2 | METHODS OF TREATING VASCULAR INJURIES | Biogen Idec MA, Inc. (US) | 2007-07-11 | — | — | EP | claimed |
| US-20060264440-A1 | Pyrazoles and methods of making and using the same | BIOGEN IDEC MA INC. (US) | 2006-11-23 | — | — | US | claimed |
| EP-1596656-A4 | PYRAZOLES AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC INC (US) | 2006-10-18 | — | — | EP | claimed |
| JP-2006517592-A | — | — | 2006-07-27 | — | — | JP | claimed |
| WO-2006044509-A2 | METHODS OF TREATING VASCULAR INJURIES | BIOGEN IDEC MA INC. (US) | 2006-04-27 | — | — | WO | claimed |
| EP-1596656-A2 | PYRAZOLES AND METHODS OF MAKING AND USING THE SAME | Biogen Idec MA Inc. (US) | 2005-11-23 | — | — | EP | claimed |
| WO-2004072033-A2 | PYRAZOLES AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. (US) | 2004-08-26 | — | — | WO | claimed |
| WO-2008013928-A2 | TREATMENT OF CANCER WITH INTERFERON GENE DELIVERY IN COMBINATION WITH A TGF-BETA INHIBITOR | BIOGEN IDEC MA INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| EP-1804801-A2 | METHODS OF TREATING VASCULAR INJURIES | Biogen Idec MA, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006044509-A2 | METHODS OF TREATING VASCULAR INJURIES | BIOGEN IDEC MA INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264440-A1 | Pyrazoles and methods of making and using the same | ALK, ACVR1, ALKBH5 | TGFBR1 26/4885MAPK14 1842/4885RIPK2 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.